Morpholino

MO1-sulf2a

ID

ZDB-MRPHLNO-060601-11

Name

MO1-sulf2a

Previous Names

MO1-sulf2

Target

sulf2a (1)

Sequence

5' - GACCTTAACCAGTGCTCCACCTCCC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

MODB:614 (2)

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO1-sulf2a

Expressed Gene	Anatomy	Figures
olig2	spinal cord motor neuron	Figure 4 , Figure 5 from Danesin et al., 2021
sim1a	spinal cord interneuron	Figure 2 from Danesin et al., 2021

Phenotype

Phenotype resulting from MO1-sulf2a

Phenotype	Fish	Figures
oligodendrocyte cell fate specification decreased occurrence, abnormal	vu17Tg + MO1-sulf2a	Figure 3 , Figure 4 from Danesin et al., 2021
spinal cord olig2 expression decreased amount, abnormal	vu17Tg + MO1-sulf2a	Figure 5 from Danesin et al., 2021
spinal cord motor neuron olig2 expression decreased amount, abnormal	vu17Tg + MO1-sulf2a	Figure 4 from Danesin et al., 2021
spinal cord oligodendrocyte decreased amount, abnormal	vu17Tg + MO1-sulf2a	Figure 3 , Figure 4 from Danesin et al., 2021
spinal cord smoothened signaling pathway increased occurrence, abnormal	vu17Tg; vu19Tg + MO1-sulf2a	Figure 8 from Danesin et al., 2021
spinal cord interneuron increased amount, abnormal	vu17Tg + MO1-sulf2a	Figure 2 , Figure 4 from Danesin et al., 2021
spinal cord interneuron sim1a expression increased amount, abnormal	WT + MO1-sulf2a	Figure 2 from Danesin et al., 2021
spinal cord interneuron cell fate specification increased occurrence, abnormal	vu17Tg + MO1-sulf2a	Figure 2 , Figure 4 from Danesin et al., 2021

Phenotype of all Fish created by or utilizing MO1-sulf2a

Phenotype	Fish	Conditions	Figures
spinal cord interneuron sim1a expression increased amount, abnormal	WT + MO1-sulf2a	standard conditions	Figure 2 from Danesin et al., 2021
spinal cord interneuron cell fate specification increased occurrence, abnormal	WT + MO1-sulf2a	standard conditions	Figure 2 from Danesin et al., 2021
spinal cord interneuron increased amount, abnormal	WT + MO1-sulf2a	standard conditions	Figure 2 from Danesin et al., 2021
spinal cord oligodendrocyte decreased amount, abnormal	vu17Tg + MO1-sulf2a	control	Figure 4 from Danesin et al., 2021
spinal cord olig2 expression decreased amount, abnormal	vu17Tg + MO1-sulf2a	control	Figure 5 from Danesin et al., 2021
spinal cord interneuron cell fate specification increased occurrence, abnormal	vu17Tg + MO1-sulf2a	control	Figure 4 from Danesin et al., 2021
spinal cord motor neuron olig2 expression decreased amount, abnormal	vu17Tg + MO1-sulf2a	control	Figure 4 from Danesin et al., 2021
spinal cord interneuron increased amount, abnormal	vu17Tg + MO1-sulf2a	control	Figure 4 from Danesin et al., 2021
oligodendrocyte cell fate specification decreased occurrence, abnormal	vu17Tg + MO1-sulf2a	control	Figure 4 from Danesin et al., 2021
oligodendrocyte cell fate specification decreased occurrence, abnormal	vu19Tg + MO1-sulf2a	standard conditions	Figure 3 from Danesin et al., 2021
spinal cord oligodendrocyte decreased amount, abnormal	vu19Tg + MO1-sulf2a	standard conditions	Figure 3 from Danesin et al., 2021
spinal cord smoothened signaling pathway increased occurrence, abnormal	vu17Tg; vu19Tg + MO1-sulf2a	standard conditions	Figure 8 from Danesin et al., 2021

Citations